Professor Dr. Sarah Blagden

Biography

Following medical training, Sarah Blagden undertook specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital in London. She was awarded the Cancer Research UK Junior Clinician Scientist PhD fellowship to study fruit fly genetics at Cambridge University from 2000 to 2004 and held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit. In 2006, she was appointed as a Senior Lecturer and Honorary Consultant at Imperial College, specializing in treating gynaecological cancers, where she launched the Imperial's Early Phase Trial portfolio and established a laboratory that studied the dysregulation of mRNA translation in cancer. In 2015, she moved to the University of Oxford as a Professor of Experimental Oncology and became the Director of the Early Phase Clinical Trials Unit. In 2021, she took leadership of the Oxford Clinical Trials Office (OCTO), managing a national trials portfolio focused on early-phase and Precision Prevention Early Detection studies. As the chief principal investigator, she has been involved in numerous national and international clinical studies, with her team's research focusing on post-transcriptional gene regulation in cancer progression.

Research Interests

Experience